<DOC>
	<DOCNO>NCT00558636</DOCNO>
	<brief_summary>The purpose study conduct Asia-Pacific evaluate efficacy safety Sorafenib combination paclitaxel carboplatin versus placebo combination paclitaxel carboplatin chemonaive patient unresectable stage IIIB ( effusion ) stage IV NSCLC . However , indicate , study terminate prematurely result Study 11961 ( NCT00300885 ) , early Phase 3 study similar design subject advance NSCLC , show overall lack efficacy increase mortality subject squamous subtype . The data available present descriptive analysis , due limitation implement statistical analysis plan .</brief_summary>
	<brief_title>A Trial Comparing Safety Efficacy Carboplatin Paclitaxel Plus Minus Sorafenib ( BAY43-9006 ) Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The study terminate early result Study 11961 ( NCT00300885 ) , early Phase 3 study evaluate effect Sorafenib combination paclitaxel carboplatin subject advance NSCLC , show overall lack efficacy Sorafenib combination paclitaxel carboplatin NSCLC increase mortality subject squamous subtype .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Stage IIIB ( cytologically confirm malignant pleural pericardial effusion ) Stage IV histological cytological confirmation NSCLC ( thoracentesis pericardiocentesis necessary biopsy original tumor available confirm diagnosis NSCLC ) Patients must measurable disease accord response evaluation criterion solid tumor ( RECIST ) criteria Prior local radiotherapy allow complete least 3 week prior first dose study drug , lesion undergo RECIST assessment field prior radiation Prior surgery allow perform least 4 week prior first dose study drug 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Life expectancy least 12 week Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start first dose : Hemoglobin 9.0 g/dl Absolute neutrophil count ( ANC ) 1,500/mm3 Platelet count 100,000/mm3 Total bilirubin &lt; 1.5 time upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement ) international normalize ratio ( INR ) &lt; 1.5 activate adjust partial thromboplastin time ( APTT ) within normal limit ( 1.2 time low limit normal ( LLN ) 1.2 time upper limit normal ( ULN ) ) Creatinine &lt; /= 1.5 time upper limit normal Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedures Any prior systemic anticancer therapy include cytotoxic therapy , target agent , experimental therapy , adjuvant , neoadjuvant therapy current prior diagnosis NSCLC Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) newonset angina ( begin within last 3 month ) myocardial infarction within past 6 month Known brain metastasis . Patients neurological symptom undergo Computed Tomography ( CT ) scan/Magnetic Resonance Imaging ( MRI ) brain exclude brain metastasis Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection Active clinically serious infection &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious , nonhealing wound , ulcer , bone fracture Evidence history bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug Therapeutic anticoagulation vitamin K antagonists warfarin , heparins heparinoids . Low dose warfarin ( 1 mg daily , oral ) permit INR remain &lt; 1.5 . Lowdose aspirin permit Known suspect allergy sorafenib agent give course trial Cancer NSCLC within 5 year prior start study treatment , EXCEPT cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor Concurrent cancer distinct primary site histology NSCLC Substance abuse , medical , psychological social condition may interfere patient participation study evaluation study result Any condition impairs patient ability swallow whole pill Any malabsorption condition Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception prior study entry duration study participation , include 30 day period last study drug dosing . The investigator advise patient achieve adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>NSCLC</keyword>
</DOC>